Overview

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

Status:
Recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

ADC Therapeutics S.A.

Treatments:

Idelalisib
Loncastuximab tesirine